About BioGene Therapeutics
BioGene Therapeutics is a private company based in Austin, Texas, incorporated in 2024 in Texas. It has reported $11,050,000 raised in five offerings on Form D since July 2026. Its chief executive is Stephen Van Deventer.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Aug 7, 2026 | $3,000,000fully sold | 1 | $3.0M | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Mar 10, 2026 | Aug 6, 2026 | $3,000,000fully sold | 1 | $3.0M | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Aug 19, 2025 | Aug 6, 2026 | $250,000fully sold | 1 | $250K | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Aug 18, 2025 | Aug 6, 2026 | $250,000fully sold | 1 | $250K | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Apr 1, 2025 | Jul 23, 2026 | $4,550,000fully sold | 6 | $758K | Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, five offerings | $11,050,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on BioGene Therapeutics's Form D filed Aug 7, 2026.
Sources
- SECBioGene Therapeutics Inc. filing history
- CompanyContact details
- CompanyPrivacy policy
- CompanyCompany overview
- CompanyPatroski Lawson appointment